Free press releases distribution network?

Agency / Source: Biocompatibles UK Ltd / BTG Plc

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



BTG International Canada Expands Operations to Directly Sell Interventional Oncology Products - DC Bead®, DC BeadM1® and Bead Block® Now Sold Directly to Specialist Physicians Across Canada - BTG-IM.com
BTG International Canada Expands Operations to Directly Sell Interventional Oncology Products

 

PRZOOM - /newswire/ - Ottawa, Ontario, Canada, 2016/03/10 - DC Bead®, DC BeadM1® and Bead Block® Now Sold Directly to Specialist Physicians Across Canada - BTG-IM.com. LSE: BTG

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

BTG International Canada, Inc., a part of the international specialty healthcare company BTG, is now selling its interventional oncology products DC Bead®, DC BeadM1® and Bead Block® direct-to-physicians in Canada. All three products were previously distributed in Canada by LivaNova PLC.

BTG has expanded its commercial presence in Canada in recent months and built an expert commercial team to directly promote and distribute its products. In 2015, BTG began selling its radioembolization product TheraSphere® and will now sell key interventional oncology products DC Bead®, DC BeadM1®, and Bead Block® directly in the Canadian marketplace.

“Being a global leader in interventional medicine, we’re proud to establish a commercial presence in Canada and pleased to begin to supply BTG products directly to healthcare professionals across the country,” said Brad Pearson, director, commercial operations at BTG International Canada Inc.

Canadian customers may call 1-844-292-1BTG (1284) to order DC Bead®, DC BeadM1®, and Bead Block® directly from BTG International Canada. To order TheraSphere® directly in Canada, customers may call BTG International Canada at 1-866-363-3330.

About DC Bead®
The gold-standard drug-eluting bead, DC Bead® is supported by more than 10 years’ experience and 100 peer-reviewed publications reporting outcomes in over 3,500 patients with liver cancer. DC Bead® has been shown in studies to offer improved clinical and patient outcomes, including excellent tolerability versus conventional TACE, and high rates of five-year survival data.1-8

Developed and manufactured by BTG, DC Bead® received Canadian approval in 2006. DC Bead® is an embolic drug-eluting bead capable of loading and releasing chemotherapeutic agents for the treatment of primary liver cancer (hepatocellular carcinoma or HCC) and liver metastases from colorectal cancers.

About DC BeadM1®
Approved in Canada in 2011, DC BeadM1® is a subset of the smallest DC Bead®. The narrow size distribution of DC BeadM1® offers greater uniformity and concentration of bead and drug distribution in the tumor.9

About Bead Block®
Bead Block® embolic beads have a unique structure PVA hydrogel cross-linked with acrylic polymer to ensure smooth delivery and targeted, effective embolization. Bead Block® received Canadian approval in 2005.

All bead products are used in minimally invasive (non-surgical) procedures performed by an interventional radiologist.

About TheraSphere®
Manufactured in Ottawa, Canada, TheraSphere® was granted a Canadian medical device license in 2002. TheraSphere® is a well-tolerated liver cancer therapy that consists of millions of small glass microspheres containing radioactive yttrium-90. The product is injected by a physician into the artery of the patient’s liver through a catheter, which allows the treatment to be delivered directly to the tumor via blood flow.

About BTG Interventional Medicine
BTG Interventional Medicine (btg-im.com) is part of BTG plc, a growing international specialist healthcare company. As medicine moves from major surgery to minor procedure, from the systemic to the local, no company endeavors to do more than BTG Interventional Medicine to help doctors in their quest to see more, reach further and treat smarter. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots, and varicose veins.

For more information:

Canadian Media Inquiries: Eileen Tobey, beSPEAK Communications Inc.
P: +1 416-540-4047 - E: Eileen[.]bespeakcommunications.com.

Investor Relations Inquiries: Andy Burrows, VP Corporate & Investor Relations
P: +44(0)20 7575 1741 / M: +44(0)79 9053 0605

References:
1. DC Bead Clinical Bibliography. Jan 2016. Available on Request
2. Varela M et al. J Hepatol 46 (2007): 474-81
3. Poon RTP et al. Clin Gastroenterol and Hepatol 5 (2007): 1100-08.
4. Lammer J et al. Cardiovasc Intervent Radiol 33 (2010): 41-52
5. Liu Y-S et al. Korean J Radiol 16 (2015): 125-132.
6. Song MJ et al. Eur J Gastroenterol Hepatol 23 (2011): 521-7.
7. Burrel M et al. J Hepatol 56 (2012): 1330-5.
8. Malagari K et al. Cardiovasc Intervent Radiol 35 (2012): 1119-28.
9. Dreher M et al. J Vasc Interv Radiol 23 (2012): 257-64.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Biocompatibles UK Ltd / BTG Plc

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


BTG International Canada Expands Operations to Directly Sell Interventional Oncology Products

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
BTG Interventional Med. |
Contact: Chris Sampson - BTGplc.com 
+44(0)20 7575 1595 / +44(0)7773 251178 (mobile) chris.sampson[.]btgplc.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Biocompatibles UK Ltd / BTG Plc securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Biocompatibles UK Ltd / BTG Plc / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  Intrinsic Executive Search Ltd

Visit  NAKIVO, Inc.

Visit  1Click Games







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today